| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Cara Therapeutics Inc (NASDAQ: CARA)
CARA Technical Analysis
5
| As on 9th Jun 2023 CARA STOCK Price closed @ 3.36 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 10.44 & Strong Sell for SHORT-TERM with Stoploss of 11.35 we also expect STOCK to react on Following IMPORTANT LEVELS. |
CARASTOCK Price
| Open | 3.28 | Change | Price | % |
| High | 3.38 | 1 Day | 0.10 | 3.07 |
| Low | 3.19 | 1 Week | 0.18 | 5.66 |
| Close | 3.36 | 1 Month | -0.69 | -17.04 |
| Volume | 896201 | 1 Year | -8.93 | -72.66 |
| 52 Week High 13.84 | 52 Week Low 3.09 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| CARA Daily Charts |
CARA Intraday Charts |
Whats New @ Bazaartrend |
CARA Free Analysis |
|
|
CARA Important Levels Intraday
| RESISTANCE | 3.73 |
| RESISTANCE | 3.61 |
| RESISTANCE | 3.54 |
| RESISTANCE | 3.46 |
| SUPPORT | 3.26 |
| SUPPORT | 3.18 |
| SUPPORT | 3.11 |
| SUPPORT | 2.99 |
CARA Forecast May 2024
| 4th UP Forecast | 8.49 |
| 3rd UP Forecast | 6.84 |
| 2nd UP Forecast | 5.83 |
| 1st UP Forecast | 4.81 |
| 1st DOWN Forecast | 1.91 |
| 2nd DOWN Forecast | 0.89 |
| 3rd DOWN Forecast | -0.12 |
| 4th DOWN Forecast | -1.77 |
CARA Weekly Forecast
| 4th UP Forecast | 5.15 |
| 3rd UP Forecast | 4.58 |
| 2nd UP Forecast | 4.22 |
| 1st UP Forecast | 3.87 |
| 1st DOWN Forecast | 2.85 |
| 2nd DOWN Forecast | 2.50 |
| 3rd DOWN Forecast | 2.14 |
| 4th DOWN Forecast | 1.57 |
CARA Forecast2024
| 4th UP Forecast | 24.6 |
| 3rd UP Forecast | 17.79 |
| 2nd UP Forecast | 13.58 |
| 1st UP Forecast | 9.37 |
| 1st DOWN Forecast | -2.65 |
| 2nd DOWN Forecast | -6.86 |
| 3rd DOWN Forecast | -11.07 |
| 4th DOWN Forecast | -17.88 |
Cara Therapeutics Inc ( NASDAQ USA Symbol : CARA )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
CARA Business Profile
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) undergoing hemodialysis. The company is also developing Oral KORSUVA (CR845/difelikefalin), which has completed Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; in Phase II clinical trial for treating pruritus chronic liver disease; and in Phase II clinical trial for the treatment of pruritus associated with atopic dermatitis. In addition, it is developing CR845/difelikefalin Injection, which has completed Phase II/III clinical trial for the treatment of acute post-operative pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut. Address: 4 Stamford Plaza, Stamford, CT, United States, 06902
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service